+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Vaccine Market Size, by Technology, Disease, Route, Patient, By Region, Trend Analysis, Competitive Market Share & Forecast, 2020-2027

  • ID: 5135085
  • Report
  • May 2020
  • Region: Global
  • 175 pages
  • Blueweave Consulting & Research Pvt Ltd
1 of 5

FEATURED COMPANIES

  • AstraZeneca (UK)
  • Bavarian Nordic (Denmark)
  • CSL Limited (Australia)
  • GlaxoSmithKline plc. (UK)
  • Johnson & Johnson (US)
  • Merck & Co. Inc. (US)
  • MORE
Vaccines, also known as immunizations, vaccinate a debilitating form of illness into a person, so the body starts creating antibodies or protection besides the disease. Real vaccination has eliminated several conditions, like polio and smallpox, with high death rates. The U.S. Food and Drug Administration newly permitted the first vaccine for dengue disease, the foremost cause of illness amid people existing in the tropics and subtropics. Vaccines can also be used after contamination occurs as a therapeutic. This kind of action has lately developed prevalent for use in immuno-oncology for cancer, making up 15 percent of immunotherapies in 2014. The vaccine market lasts to show development, although the anti-vaccine movement. In the U.S., this drive has created an atmosphere of suspicion around vaccines, despite growing indications of vaccines' safety and efficacy. The World Health Organization has named vaccine hesitancy as one of the top ten threats fronting public health this year.

The high occurrence rate of infectious diseases and other chronic conditions in the country. Growing aging population base, along with many initiatives taken by the government of India to expand the provision of vaccines in the nation, will positively influence business development. Companies operating in the vaccines market are concentrating on gripping untapped market potential in the country, thereby pushing the market development.

Moreover, the growth of new and improved immunizations for several diseases is a major factor predictable to push growth. The occurrence of several pipeline drugs is expected to lead the development of the Vaccine Market.

The surge in the occurrence of infectious diseases in France, including measles, has stimulated the demand for vaccines in the country after high CAGR during the forecast period. Furthermore, many labors assumed by the French health bodies to make mindfulness about vaccines through social media platforms, including LinkedIn, Facebook, Twitter, have motivated the acceptance of vaccines in France.

North America accounted for a significant portion of the vaccine market in 2018. The large share of North America in the global vaccines market is credited to the high occurrence of infectious diseases and growing savings by government and non-government organizations for vaccine development. On the other hand, the market in Asia is predicted to list the highest growth during the prediction period. Factors such as the growing healthcare spending and growing disposable income, government initiatives, and the occurrence of a large patient people are motivating the growth of the vaccine market in Asia.

The Asia Pacific region is predictable to bystander the firmest development over the prediction period, credited by the rising target people base with high-unmet clinical needs. In addition, the growing disposable income level and the increasing mindfulness regarding the merits of vaccination in emerging economies of the Asia Pacific region are further predictable to foster market development.

Growth Drivers

Increase in incidence of both viral and bacterial infectious diseases

An escalation in communicable diseases universal, including Ebola, influenza, swine flu, hepatitis, tuberculosis, diphtheria, and meningococcal and pneumococcal diseases, is one of the chief drivers of market growth. Vaccinations are essentially administered to people of different age groups, which strengthens their resistant system during a lifetime and offers protection against dissimilar types of infectious diseases - besides, emerging vaccines (Zika vaccines, dengue vaccines, cancer vaccines, and others), making of technologically advanced vaccines, advancements in vaccine delivery devices, and increase in immunization programs addition the market growth.

Strong Supply backed up by Robust R&D to drive the Vaccines Market

One of the vital and noteworthy drivers for market growth is the growing source of vaccines crosswise the sphere to meet the unmet needs and abide by the immunization policies to eradicate widespread diseases. Pharmaceutical companies, government foundations, international organizations, and hospitals are strongly absorbed in providing cost-effective and regular vaccination to people universal. A government investigation in all the countries has become active in safeguarding that suggested Vaccines at a minimum cost or no cost vaccinate every individual.


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca (UK)
  • Bavarian Nordic (Denmark)
  • CSL Limited (Australia)
  • GlaxoSmithKline plc. (UK)
  • Johnson & Johnson (US)
  • Merck & Co. Inc. (US)
  • MORE
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary research respondent, By Region
2.5. Assumption & Limitation

3. Executive Summary

4. Global Vaccine market Industry Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraint
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape/Recent Development
4.4. Regulatory Framework
4.5. Company Market Share Analysis, 2019
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of New Entrants
4.6.4. Threat of Substitutes
4.6.5. Intensity of Rivalry
4.7. Impact of COVID 19

5. Global Vaccine market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Technology
5.2.1.1. Live
5.2.1.2. Toxoid
5.2.1.3. Recombinant
5.2.2. By Disease
5.2.2.1. Pneumococcal
5.2.2.2. Influenza
5.2.2.3. DTP
5.2.2.4. Rotavirus
5.2.2.5. TT
5.2.2.6. Polio
5.2.2.7. MMR
5.2.2.8. Varicella
5.2.2.9. Dengue
5.2.2.10. TB,
5.2.2.11. Shingles
5.2.2.12. Rabies
5.2.3. By Route
5.2.3.1. IM
5.2.3.2. SC
5.2.3.3. ID
5.2.3.4. Oral
5.2.4. By Patient
5.2.4.1. Pediatric
5.2.4.2. Adult
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia Pacific
5.2.5.4. Latin America
5.2.5.5. Middle East & Africa

6. North America Vaccine Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Disease
6.2.3. By Route
6.2.4. By Patient
6.2.5. By Country
6.2.5.1. United States
6.2.5.2. Canada

7. Europe Vaccine market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Disease
7.2.3. By Route
7.2.4. By Patient
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. United Kingdom
7.2.5.3. France
7.2.5.4. Italy
7.2.5.5. Spain
7.2.5.6. Rest of Europe

8. Asia Pacific Vaccine Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Disease
8.2.3. By Route
8.2.4. By Patient
8.2.5. By Country
8.2.5.1. India
8.2.5.2. China
8.2.5.3. Japan
8.2.5.4. South Korea
8.2.5.5. Rest of Asia Pacific

9. Latin America Vaccine Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1.1. By Technology
9.2.1.2. By Disease
9.2.1.3. By Route
9.2.1.4. By Patient
9.2.1.5. By Country
9.2.1.5.1. Brazil
9.2.1.5.2. Mexico
9.2.1.5.3. Rest of Latin America

10. Middle East & Africa Vaccine Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1.1. By Technology
10.2.1.2. By Disease
10.2.1.3. By Route
10.2.1.4. By Patient
10.2.1.5. By Country
10.2.1.5.1. Saudi Arabia
10.2.1.5.2. UAE
10.2.1.5.3. South Africa
10.2.1.5.4. Rest of Middle East & Africa

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)*
11.1. Glaxosmithkline PLC
11.2. Pfizer, Inc
11.3. Merck & Co., Inc
11.4. Sanofi Pasteur SA
11.5. CSL Limited
11.6. Emergent Biosolutions, Inc
11.7. Johnson & Johnson
11.8. Astrazeneca
11.9. Serum Institute of India Pvt., LTD
11.10. Bavarian Nordic
11.11. Mitsubishi Tanabe Pharma Corporation
11.12. Daiichi Sankyo Company, Limited
11.13. Panacea Biotec, LTD
11.14. Biological E
11.15. Bharat Biotech .
11.16. Other Prominent Players
* Financial details in case of unlisted companies will be available as per data availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • GlaxoSmithKline plc. (UK)
  • Pfizer Inc. (US)
  • Merck & Co. Inc. (US)
  • Sanofi Pasteur SA (France).
  • CSL Limited (Australia)
  • Emergent BioSolutions Inc. (US)
  • Johnson & Johnson (US)
  • Serum Institute of India (India)
  • AstraZeneca (UK)
  • Bavarian Nordic (Denmark)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Daiichi Sankyo Company Limited (Japan).
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll